2016 Press Releases

Keyword Search
 
DateTitle 
09/07/16Neurocrine Biosciences to Present at the Morgan Stanley Global Healthcare Conference
Live Audio Webcast will be on September 13, 2016 SAN DIEGO, Sept. 7, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Morgan Stanley Healthcare Conference in New York City. The live presentation takes place on Tuesday, September 13 at 11:10am ET (8:10am PT).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.   ... 
Printer Friendly Version
09/01/16Neurocrine Biosciences to Present at the Baird 2016 Healthcare Conference
Live Audio Webcast will be on September 7, 2016 SAN DIEGO, Sept. 1, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Baird 2016 Healthcare Conference in New York City. The live presentation takes place on Wednesday, September 7 at 11:25am ET (8:25am PT).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.   Li... 
Printer Friendly Version
08/31/16Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA™ for VMAT2 Inhibitor Valbenazine
SAN DIEGO, Aug. 31, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name "INGREZZA™" for the Company's once-daily vesicular monoamine transporter 2 (VMAT2) inhibitor valbenazine. The Company has recently announced the submission of a New Drug Application (NDA) with the FDA for valbenazine in tardive dyskinesia and is also exploring its utility in Tourette syndrome.   Th... 
Printer Friendly Version
08/29/16Neurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia
SAN DIEGO, Aug. 29, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-daily dosing of valbenazine in treating tardive dyskinesia. "This is an important milestone in the development of valbenazine for the treatment of tardive dyskinesia, a serious disease for which there is no FDA approved pharmaceutical treatment," said Kevin C. Gorman, President and Chief... 
Printer Friendly Version
08/03/16Neurocrine Biosciences Reports Second Quarter 2016 Results
-Valbenazine New Drug Application for Tardive Dyskinesia to be Submitted in 2016- - Valbenazine Presentations at Three Major Scientific Conferences during Second Quarter- -Long-Term Tourette Syndrome Study Initiated- -NBI-640756 for Essential Tremor Moves into Second Phase I Study- SAN DIEGO, Aug. 3, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended June 30, 2016.  For the second quarter of 2016, the Company re... 
Printer Friendly Version
07/28/16Neurocrine Announces Initiation of a Long-Term Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Tourette Syndrome
Six Month Open Label Safety and Tolerability Study of Valbenazine SAN DIEGO, July 28, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase II clinical trial for NBI-98854 (valbenazine), a highly selective small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in children, adolescents and adults with Tourette syndrome. This study is an open-label, fixed-dose, study of up to 180 male and female patients with Tourette syn... 
Printer Friendly Version
07/27/16Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2016 Results
Conference Call and Webcast Scheduled For Wednesday, August 3, 2016 SAN DIEGO, July 27, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2016 results after the Nasdaq market closes on Wednesday, August 3, 2016.  Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Wednesday afternoon, August 3, 2016 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific T... 
Printer Friendly Version
06/02/16Neurocrine Biosciences to Present at the Jefferies 2016 Healthcare Conference
Live Audio Webcast will be on June 8, 2016 SAN DIEGO, June 2, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Jefferies 2016 Healthcare Conference in New York City. The live presentation takes place on Wednesday, June 8 at 10:30am ET (7:30am PT).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.   Listeners... 
Printer Friendly Version
05/20/16Neurocrine Biosciences Announces the Retirement of W. Thomas Mitchell from the Board of Directors
SAN DIEGO, May 20, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that W. Thomas Mitchell has notified the Company that he is retiring from the Board of Directors effective just prior to the 2016 Annual Meeting of Shareholders. Mr. Mitchell has been a member of the Board of Directors for over thirteen years serving in various capacities on the audit, compensation, and nominating and corporate governance committees. "Tom has been an integral member of the Boa... 
Printer Friendly Version
05/06/16Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
Live Audio Webcast will be on May 12, 2016 SAN DIEGO, May 6, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas. The live presentation takes place on Thursday, May 12 at 10:00am PT (1:00pm ET).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com. ... 
Printer Friendly Version
05/06/16Neurocrine Biosciences Announces Additional Valbenazine (NBI-98854) Data to be Presented at the American Psychiatric Association's 2016 Annual Meeting in Atlanta
Four Abstracts Submitted and Accepted for the May 2016 APA Annual Meeting SAN DIEGO, May 6, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that four abstracts representing additional data from both the Kinect 3 and Kinect 2 tardive dyskinesia clinical trials of valbenazine will be presented at the American Psychiatric Association Annual Meeting in May. The four posters will include an evaluation of the impact of valbenazine on the psychiatric stability of sub... 
Printer Friendly Version
05/05/16Neurocrine Biosciences Reports First Quarter 2016 Results
-Valbenazine New Drug Application for Tardive Dyskinesia to be Filed in 2016- -Kinect 4 Fully Enrolled, Valbenazine Presentations at Major Scientific Conferences in Second Quarter- -AbbVie Reports Positive Top-Line Efficacy from Second Elagolix Endometriosis Phase III Study, Initiates Two Phase III Studies of Elagolix in Uterine Fibroids- SAN DIEGO, May 5, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31... 
Printer Friendly Version
04/29/16Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2016 Results
Conference Call and Webcast Scheduled For Thursday, May 5, 2016 SAN DIEGO, April 29, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2016 results after the Nasdaq market closes on Thursday, May 5, 2016.  Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday afternoon, May 5, 2016 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Par... 
Printer Friendly Version
04/27/16Neurocrine Biosciences to Present at the Deutsche Bank 41st Annual Health Care Conference
Live Audio Webcast will be on May 4, 2016 SAN DIEGO, April 27, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Deutsche Bank  41st Annual Health Care Conference in Boston. The live presentation takes place on Wednesday, May 4 at 2:50pm ET (11:50am PT).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.   Lis... 
Printer Friendly Version
03/09/16Neurocrine Biosciences to Present at the Barclays Global Healthcare Conference
Live Audio Webcast will be on March 15, 2016 SAN DIEGO, March 9, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Barclays Global Healthcare Conference in Miami Beach. The live presentation takes place on Tuesday, March 15 at 4:20pm ET (1:20pm PT).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.   Listen... 
Printer Friendly Version
03/02/16Neurocrine Biosciences to Present at the Cowen and Company 36th Annual Health Care Conference
Live Audio Webcast will be on March 9, 2016 SAN DIEGO, March 2, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Cowen and Company 36th Annual Health Care Conference in Boston. The live presentation takes place on Wednesday, March 9 at 10:00am ET (7:00am PT). The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine... 
Printer Friendly Version
03/02/16Neurocrine Biosciences Announces the Acceptance of Three Scientific Abstracts for Valbenazine (NBI-98854) at the 68th Annual Meeting of the American Academy of Neurology in Vancouver April 2016
Kinect 3 Clinical Study Data Accepted for Plenary Session Data From all Three Kinect Clinical Studies will be Presented SAN DIEGO, March 2, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that on April 20, 2016, data from the Phase III Kinect 3 study of valbenazine (NBI-98854) for tardive dyskinesia will be presented during a plenary session at the American Academy of Neurology Annual Meeting in Vancouver. In addition, data from the Kinect 1 and Kinect 2 cl... 
Printer Friendly Version
02/11/16Neurocrine Biosciences Reports Year-End 2015 Results and Provides Investor Update for 2016
Valbenazine New Drug Application to be filed for Tardive Dyskinesia this Year Second Elagolix Phase III Study in Endometriosis is Successful Two Phase III Studies of Elagolix in Uterine Fibroids Underway Two Phase II Studies of Valbenazine in Tourette Syndrome Expected to Readout Near Year-End Two Clinical Trial Readouts Expected in 2016 from Essential Tremor Drug Candidate NBI-640756 SAN DIEGO, Feb. 11, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announc... 
Printer Friendly Version
02/10/16AbbVie Announces Positive Top-Line Results From Second Phase 3 Study Investigating Elagolix in Patients with Endometriosis
- Study meets co-primary efficacy endpoints and full results will be presented at a medical conference in 2016 - Results show Elagolix reduces endometriosis-associated pain (menstrual and non-menstrual pelvic pain) compared to placebo - New Drug Application for endometriosis anticipated in 2017 NORTH CHICAGO, Ill., Feb. 10, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced positive top-line resul... 
Printer Friendly Version
02/08/16Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2015 Results
Conference Call and Webcast Scheduled For Thursday, February 11, 2016 SAN DIEGO, Feb. 8, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2015 results after the Nasdaq market closes on Thursday,  February 11, 2016.  Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday afternoon, February 11, 2016 at 4:30 p.m. Eastern Time (... 
Printer Friendly Version
02/03/16Neurocrine Biosciences to Present at the Leerink Partners 5th Annual Global Healthcare Conference
Live Audio Webcast will be on February 10, 2016 SAN DIEGO, Feb. 3, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Leerink Partners 5th Annual Global Healthcare Conference in New York City. The live presentation takes place on Wednesday, February 10 at 11:55am ET (8:55am PT).  The presentation will be webcast and may be accessed on the Company's website at http://www.n... 
Printer Friendly Version
02/02/16Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome
Six-Week T-Force GREEN Study to Assess the Safety, Tolerability and Efficacy of Valbenazine in 90 Pediatric Subjects SAN DIEGO, Feb. 2, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated a Phase II clinical trial for NBI-98854 (valbenazine), a highly selective small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in children and adolescents with Tourette syndrome.   The T-Force GREEN study is a randomized, double-blind, plac... 
Printer Friendly Version
01/28/16AbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids
- The Elagolix Phase 3 uterine fibroid clinical development program includes two replicate, pivotal, six-month efficacy and safety studies followed by a six-month safety and efficacy extension study. - Primary endpoint is percent of subjects with reduction in uterine blood flow as measured by the alkaline hematin method. NORTH CHICAGO, Ill., Jan. 28, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the... 
Printer Friendly Version
01/04/16Neurocrine Biosciences to Present at the 34th Annual J.P. Morgan Healthcare Conference
Live Audio Webcast will be on January 11, 2016 SAN DIEGO, Jan. 4, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco.   The live presentation takes place on Monday, January 11 at 8:00am PT (11:00am ET).  The presentation will be webcast and may be accessed on the Company's website at http:... 
Printer Friendly Version